You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a sensitive method to measure heparan sulfate 6-O-endosulfatase

    SBC: GLYCAN THERAPEUTICS CORPORATION            Topic: 300

    The proposal is aimed to develop a sensitive method to measure the activity of heparan sulfate 6-O-endosulfatase (SULF). SULF is an enzyme that removes the 6-O-sulfo groups from heparan sulfate polysaccharides to modulate the functions of heparan sulfate. Evidence has demonstrated that the level of SULF contributes to the progression of cancers; however, the method that measures the activity from ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Non-invasive molecular imaging tool for rapid, longitudinal assessment of localized metabolic disruptions in animal research and care

    SBC: VIZMA LIFE SCIENCES INC            Topic: 100

    PROJECT SUMMARY The cellular pathophysiology that underlies diseases, such as cancer, cardiovascular disease, and diabetes, begins to change long before disease symptoms become apparent. Moreover, current imaging techniques typically only visualize morphology and structure. Therefore, imaging techniques that can characterize metabolic changes have the potential to detect disease processes long bef ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Arecombinant elastin skin substitute for the treatment of burns

    SBC: INSOMA BIO, INC.            Topic: 300

    Project SummaryThe goal of this project is to optimize and evaluate inSoma Bio’s proprietary recombinant elastin-based biomaterial, Fractomer®, as an effective, low-cost skin grafting support matrix for the treatment of severe burn wounds. Burns are most successfully treated by surgical excision followed by skin grafting; however many patients with severe damage do not have sufficient healthy s ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. The SE-Learn Online Professional Development Platform for Enhanced Social Emotional Learning with Students

    SBC: 3-C Institute for Social Development, Inc.            Topic: 104

    Abstract Considerable evidence demonstrates how children’s social emotional (SE) development plays a significant role in their academic achievement, behavior, and emotional wellbeing. As the scientific base has grown supporting the positive impact of social and emotional learning (SEL) instructional practices, efforts to integrate SEL into academic settings has gained momentum, with teachers inc ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. PA TH2Caregiving: Data-Driven Digital Engagement to Assess and Address the Needs of Family Caregivers

    SBC: PATH2CAREGIVING LLC            Topic: 600

    PROJECT SUMMARY/ABSTRACT Family caregivers are often required to provide post-discharge assistance to individuals with disabling conditions, resulting in strain and negative effects on the caregiver’s health and well-being. While assessing and addressing the needs of family caregivers has been identified as a priority area, there are no comprehensive programs designed to assess a family member†...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Peptide Immunomodulators for Treating Sepsis

    SBC: ELDEC PHARMACEUTICALS INC.            Topic: NIAID

    Novel Peptide Immunomodulators for Treating Sepsis Sepsis is a life-threatening clinical condition which results from a dysregulation of host immune responses to infection, which leads to multi-organ failure. Sepsis occurs in ~1.7 million US adults annually resulting in hospitalization and 270,000 deaths. Of those that survive, nearly 50% of sepsis patients are re-hospitalized and one in six of su ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of the OpiAID strength band platform

    SBC: OpiAID, LLC            Topic: NIDA

    PROJECT SUMMARY Opioid misuse has reached epidemic levels in the U.S., claiming the lives of more than 104,000 people in the twelve months up to February 2022 alone. Opioids are highly addictive and are accompanied by severe withdrawal symptoms such as anxiety, generalized pain, insomnia, and flu-like symptoms that contribute to relapse. Opioid overdose, misuse, and dependence result in an estimat ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Novel Injectable Antibiotic to Treat Serious Multidrug-resistant Gram-positive Infections

    SBC: AIMMAX THERAPEUTICS INC            Topic: NIAID

    PROJECT SUMMARY / ABSTRACT Within the past decades, the prevalence of antibiotic-resistant (AMR) gram-positive infections have increased, and gram-positive bacteria cause the majority of nosocomial infections. It was estimated that in 2019 there were 4.95 million deaths associated with AMR and 1.27 million deaths directly attributable to AMR. In high income countries, Staphylococcus aureus was the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Scalable and quantitative chromatin profiling from formalin-fixed paraffin-embedded samples

    SBC: Epicypher, Inc.            Topic: 172

    PROJECT SUMMARYThe development of tools to map the location of histone post-translational modifications (PTMs) genome- wide has ushered in a new era of epigenetic research, placing histone PTMs and associated mechanisms in the spotlight as novel biomarkers and therapeutic targets. Despite this progress, leveraging epigenomics for clinical research has been hindered by a lack of high-performance ge ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Protein depleting pre-existing antibodies for viral gene therapy

    SBC: NEUROGT INC            Topic: NIAID

    Project Summary: This is a fast-track SBIR grant proposal. As effective gene therapy (GT) products using adeno-associated viral (AAV) vectors advance to clinical applications, the translation faces critical challenge of high prevalence of αAA) antibodies (Abs) in humans. Currently, only individuals negative of αAAV-Abs are eligible for AAV GT treatment. The goal of this SBIR project is to develo ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government